This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Crane's (CR) Q2 Earnings and Revenues Beat, '18 View Up
by Zacks Equity Research
Crane's (CR) impressive second-quarter 2018 earnings were driven by strong performance of its Fluid Handling and Payment & Merchandising Technologies segments.
What's in the Cards for Waters Corp (WAT) in Q2 Earnings?
by Zacks Equity Research
Waters Corp (WAT) is scheduled to report second-quarter results which are likely to be driven by its strong position in the pharmaceutical market and robust mass spectrometry portfolio.
Taiwan Semi (TSM) Q2 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Taiwan Semi (TSM) reported second-quarter 2018 results wherein both earnings and revenues improved year over year.
Harris Wins IDIQ Contracts to Enhance Geospatial Databases
by Zacks Equity Research
Harris (HRS) has been in a partnership with the National Geospatial-Intelligence Agency for more than 20 years, providing automated geospatial data processing.
Fortive Set to Buy Gordian, Expands Field Solutions Portfolio
by Zacks Equity Research
Fortive's (FTV) plans to acquire Gordian. The buyout is likely to add strength to Professional Instrumentation and Industrial Technologies segments.
Comtech (CMTL) to Offer Transportable Troposcatter Systems
by Zacks Equity Research
Comtech's (CMTL) subsidiary, Comtech Systems, secures an order for its Modular Transportable Transmission System troposcatter terminals from a foreign subsidiary.
Comtech Wins $3.6M Follow-On Contract Award for RF Amplifiers
by Zacks Equity Research
Comtech's (CMTL) subsidiary, Comtech PST Corp, receives a follow-on contract award from a leading medical instrumentation provider.
Verizon's MERIT Ready to Protect Network Assets & Facilities
by Zacks Equity Research
Verizon's (VZ) specialized team of engineers known as MERIT finishes their annual training.
Fortive Plans to Buy Johnson & Johnson's Sterilization Unit
by Zacks Equity Research
Fortive (FTV) is likely to enter the medical sterilization and disinfection market with its intended purchase of Johnson & Johnson's Sterilization business.
Why is AMETEK (AME) Up 6.5% Since Its Last Earnings Report?
by Zacks Equity Research
AMETEK (AME) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Cognex (CGNX) Could Be Positioned for a Slump
by Zacks Equity Research
Cognex (CGNX) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
AMETEK (AME) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
AMETEK (AME) reports first quarter results driven by benefits from acquisitions and strong organic sales.
AMETEK, Inc. (AME) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AMETEK, Inc. (AME) Sees Hammer Chart Pattern: Time to Buy?
Taiwan Semi (TSM) Q1 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Taiwan Semi's (TSM) Q1 earnings miss estimates but revenues grow year over year on the back of increased demand from cryptocurrency mining.
Itron (ITRI) and sonnen Team Up to Maximize Grid Efficiency
by Zacks Equity Research
Itron (ITRI) partners with sonnen group to help utilities to effectively control and manage stored energy resources by maximizing grid efficiency.
Here's Why You Should Hold on to Itron (ITRI) Stock for Now
by Zacks Equity Research
Itron (ITRI) expected to benefit from focus on restructuring, acquisitions and backlog strength despite elevated expenses.
Romanian Utility Selects Itron Meters to Reduce Water Loss
by Zacks Equity Research
Itron's (ITRI) deal with Romanian water utility, SC CUP Dunarea Braila SA, will help reduce water losses. It will partner with a local company, Vestra, to deploy 30,000 Itron Flodis/Flostar M meters.
Agilent's AATI Acquisition to Strengthen Portfolio, Footprint
by Zacks Equity Research
Agilent (A) is set to acquire AATI, a developer of automated nucleic acid analysis systems using capillary electrophoresis methods, for $250 million.
Itron to Grow on Silver Spring Acquisition Amid Rising Costs
by Zacks Equity Research
The Silver Spring acquisition, focus on restructuring and backlog strength anticipated to drive Itron's (ITRI) performance in the near term despite elevated expenses.
Itron (ITRI) Tops Q4 Earnings & Revenues, Guides for 2018
by Zacks Equity Research
Itron (ITRI) is anticipated to benefit from Silver Spring Networks acquisition in 2018.
Agilent (A) Q1 Earnings & Revenues Beat, '18 View Positive
by Zacks Equity Research
Agilent (A) first-quarter fiscal 2018 results benefit from robust top-line growth and improving end-market demand.
Fortive (FTV) Beats on Q4 Earnings & Revenues, Gives '18 View
by Zacks Equity Research
Fortive's (FTV) fourth-quarter 2017 results are driven by strong revenues growth. Acquisitions contribute 5.9% to top-line growth.
AMETEK (AME) Beats on Q4 Earnings, Organic Revenues Up Y/Y
by Zacks Equity Research
AMETEK reported earnings of 70 cents per share, which beat the Zacks Consensus Estimate by three cents.
Teradyne, Inc. (TER) Jumps: Stock Rises 6.5%
by Zacks Equity Research
Teradyne (TER) was a big mover last session, as the company saw its shares nearly 6% on the day amid huge volumes.
Amphenol Hits 52-Week High: More Upside in Store for 2018?
by Zacks Equity Research
Improved end-market demand, bullish outlook for 2017 and core focus perhaps boosted investors' confidence and catapulted Amphenol's (APH) shares to a new 52-week high.